Drugs / Immucillin DI4G
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03294161 | Dec 2014 → Apr 2017 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immucillin DI4G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03294161 ↗ |
| Action | Inhibit | “Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase” NCT03294161 ↗ |
| Route | Topical | “administered by topical use at 2% concentration” NCT03294161 ↗ |